introduct
cali
druce
report
ivermectin
inhibit
vitro
h
use
ivermectin
concentr
result
inhibit
higher
maximum
plasma
concentr
cmax
oral
administr
approv
dose
ivermectin
given
fast
method
simul
conduct
use
avail
popul
pharmacokinet
model
predict
total
bound
unbound
unbound
plasma
concentrationtim
profil
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
singl
repeat
fast
administr
approv
dose
ivermectin
mg
mg
plasma
total
cmax
determin
multipli
lung
plasma
ratio
report
cattl
predict
lung
cmax
administr
singl
dose
result
plasma
ivermectin
concentr
total
bound
unbound
unbound
concentr
reach
even
dose
level
higher
approv
dose
even
higher
exposur
lung
plasma
ivermectin
unlik
reach
lung
singl
oral
administr
approv
dose
predict
lung
dose
higher
approv
dose
administ
oral
predict
lung
likelihood
success
clinic
trial
use
approv
dose
ivermectin
low
combin
therapi
evalu
vitro
repurpos
drug
use
treatment
ideal
strategi
feasibl
product
safeti
establish
experi
repurpos
drug
conduct
clinic
relev
concentr
recent
articl
cali
druce
report
ivermectin
inhibit
vitro
caus
reduct
viral
rna
h
ivermectin
concentr
result
inhibit
ngml
higher
maximum
plasma
concentr
cmax
ngml
oral
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
administr
approv
dose
sinc
ivermectin
high
protein
bind
order
magnitud
higher
unbound
plasma
cmax
approv
dose
ivermectin
ngml
order
understand
vitro
inhibit
ivermectin
translat
human
one
must
first
evalu
concentr
compar
predict
lung
concentr
human
oral
administr
ivermectin
ivermectin
reach
lung
oral
dose
like
relat
unbound
concentr
plasma
lipophil
transport
may
help
maintain
tissu
distribut
ivermectin
concentr
lung
tissu
measur
human
ivermectin
lung
exposur
report
higher
total
plasma
exposur
cattl
singl
dose
even
higher
concentr
lung
ivermectin
unlik
reach
oral
administr
approv
dose
human
unlik
narrow
therapeut
index
hydroxychloroquin
chloroquin
ivermectin
wider
safeti
margin
safeti
higher
dose
ivermectin
evalu
phase
studi
dose
studi
patient
dengu
fever
even
higher
dose
higher
approv
dose
studi
small
phase
trial
trial
show
ivermectin
administ
oral
fast
state
well
toler
singl
mg
dose
higher
approv
dose
mg
three
time
weekli
everi
hour
advers
experi
similar
ivermectin
placebo
increas
dose
dose
regimen
mydriat
effect
primari
safeti
endpoint
base
result
toxicolog
studi
similar
placebo
import
note
studi
evalu
common
advers
event
presenc
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
incid
rare
advers
event
high
dose
unknown
given
small
number
subject
studi
overal
object
analysi
evalu
dose
human
would
predict
result
lung
concentr
reach
lung
help
design
success
clinic
trial
ivermectin
treatment
popul
pharmacokinet
model
ivermectin
report
duthal
suenderhauf
use
simul
model
twocompart
model
transit
absorpt
model
firstord
elimin
weight
covari
central
volum
distribut
clearanc
model
develop
healthi
subject
receiv
singl
ivermectin
dose
mg
fed
state
simul
perform
use
nonmem
version
icon
total
bound
unbound
plasma
concentrationtim
profil
simul
predict
exposur
approv
dose
ivermectin
mg
increment
mg
studi
guzzo
furtek
singl
dose
sinc
ivermectin
concentr
remain
steadi
cattl
lung
day
declin
addit
day
singl
subcutan
dose
addit
simul
conduct
predict
plasma
concentr
weekli
dose
addit
mg
administ
three
time
weekli
simul
everi
hour
given
dose
studi
healthi
subject
guzzo
furtek
bodi
weight
sampl
center
diseas
control
weight
chart
assum
year
old
adult
male
femal
ratio
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
popul
pharmacokinet
model
built
base
subject
receiv
ivermectin
highfat
breakfast
bioavail
increas
increas
fed
state
chang
tmax
ivermectin
taken
empti
stomach
water
plasma
concentrationtim
data
divid
geometr
least
squar
mean
ratio
fed
fast
predict
concentr
ivermectin
administ
fast
state
unbound
plasma
concentrationtim
data
predict
multipli
total
concentr
unbound
fraction
cmax
valu
total
plasma
concentr
determin
multipli
lung
plasma
ratio
cattl
report
lifschitz
virkel
singl
dose
deriv
cmax
valu
total
lung
concentr
lung
plasma
ratio
repeat
dose
could
determin
without
model
data
cattl
accumul
expect
lung
plasma
weekli
weekli
administr
need
investig
experiment
data
ballpark
accumul
ratio
ar
lung
calcul
use
equat
ke
estim
elimin
rate
constant
cattl
lung
concentrationtim
profil
present
lifschitz
virkel
tau
dose
interv
plasma
ivermectin
concentr
total
bound
unbound
unbound
concentr
reach
report
cali
druce
even
dose
level
higher
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
approv
dose
repeat
dose
figur
plasma
exposur
increas
substanti
repeat
dose
limit
ivermectin
accumul
plasma
time
weekli
weekli
dose
even
higher
exposur
lung
ivermectin
unlik
reach
lung
singl
oral
administr
approv
dose
predict
lung
concentr
dose
higher
approv
dose
administ
oral
predict
lung
concentr
tabl
current
lung
tissu
disposit
data
avail
repeat
dose
would
reach
lung
unless
accumul
lung
ivermectin
approv
dose
administ
weekli
mg
administ
weekli
ivermectin
mg
everi
hour
approv
dose
administ
three
time
weekli
ballpark
accumul
ratio
lung
tissu
would
result
lung
concentr
th
approv
dose
administ
daili
ballpark
accumul
ratio
lung
tissu
would
result
lung
concentr
th
vitro
studi
show
ivermectin
inhibit
conduct
concentr
substanti
higher
predict
plasma
lung
concentr
human
receiv
approv
dose
ivermectin
therefor
likelihood
success
clinic
trial
use
approv
dose
ivermectin
low
clinic
trial
conduct
wellcontrol
doserespons
studi
consid
feasibl
ivermectin
inhal
treatment
evalu
first
step
would
repeat
vitro
studi
report
cali
druce
compound
could
theoret
potenti
ivermectin
inhibit
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
identifi
whether
concentr
rather
could
inhibit
repurpos
drug
use
treatment
ideal
strategi
feasibl
safeti
product
use
establish
dose
level
produc
efficaci
therefor
vitro
experi
repurpos
drug
conduct
clinic
relev
concentr
soon
vitro
find
publish
clinician
world
use
ivermectin
offlabel
patel
et
al
report
week
observ
registrybas
studi
hospit
across
world
ivermectin
administ
patient
institut
mechan
ventil
show
potenti
decreas
hospit
stay
length
surviv
benefit
compar
conventionallytr
patient
note
result
account
comorbid
might
account
differ
nevertheless
ivermectin
contribut
clinic
find
would
suggest
vitro
find
cali
druce
correl
small
amount
drug
site
action
human
concentr
drug
need
reach
clinic
benefit
distribut
lung
human
greater
cattl
accumul
lung
tissu
much
greater
expect
repeat
dose
clinic
studi
conduct
ivermectin
would
import
conduct
wellcontrol
clinic
doserespons
studi
ivermectin
low
dose
approv
dose
lower
likelihood
success
higher
dose
rel
placebo
patient
ideal
higher
dose
ivermectin
establish
ivermectin
dose
mg
administ
small
number
subject
daili
dose
ivermectin
lung
concentr
predict
around
th
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
daili
dose
ivermectin
approv
dose
longer
period
eg
day
studi
small
studi
seriou
infect
unapprov
subcutan
formul
use
therefor
higher
dose
studi
weekli
approv
dose
studi
daili
parenter
formul
use
subject
need
monitor
close
addit
studi
would
need
control
factor
affect
variabl
exposur
ivermectin
includ
administ
dose
fast
state
exclud
pglycoprotein
inhibitor
lastli
potenti
longerterm
solut
would
consid
whether
inhal
treatment
ivermectin
feasibl
inhal
treatment
would
allow
higher
concentr
site
action
limit
system
exposur
may
requir
studi
safeti
toler
anim
prior
human
exposur
one
nonclin
studi
publish
inhal
ivermectin
noobservedadverseeffect
level
noael
day
inhal
ivermectin
identifi
mgm
studi
use
inhal
rout
administr
identifi
human
key
import
determin
whether
ivermectin
gener
properti
would
allow
inhal
local
toler
issu
expert
must
therefor
evalu
whether
ivermectin
possess
ideal
properti
inhal
whether
inhal
ivermectin
pose
theoret
risk
might
limit
rout
administr
overal
result
identifi
paper
cali
druce
creat
opportun
interdisciplinari
collabor
help
understand
highest
probabl
success
ivermectin
treatment
prior
explor
clinic
studi
wors
yet
offlabel
use
gener
public
lessthanid
dose
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doiorg
current
knowledg
topic
cali
druce
report
ivermectin
inhibit
vitro
higher
cmax
oral
administr
approv
dose
ivermectin
ivermectin
dose
reach
lung
oral
administr
human
ivermectin
unlik
reach
lung
oral
administr
approv
dose
dose
higher
approv
dose
singl
dose
approv
dose
ivermectin
alon
low
probabl
success
treatment
repurpos
drug
use
treatment
ideal
strategi
feasibl
product
safeti
establish
experi
repurpos
drug
conduct
clinic
relev
concentr
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
lifschitz
et
al
ci
confid
interv
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
